Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

This study is looking at the safety and efficacy of a new type of BTK inhibitor called Nemtabrutinib. BTK inhibitors target and kill a type of protein called BTK, which helps cancer cells grow. Sometimes BTK proteins can mutate (change), which means BTK inhibitors can no longer ‘find’ and kill them. This makes the drugs less effective in the long term. Nemtabrutinib is different to other BTK inhibitors in that it can still target BTK proteins that have mutated.
The study is split into two parts that will help researchers understand what the best dose of the drug is.